Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 13.82 is 41% above its 5-year average of 9.81, near the high end of its 5-year range (5.20–14.94).
As of the fiscal period ended Tuesday, June 30, 2026. 40.66% above its 12-month average of 9.83.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.82.
QUICK RATIO (ACID-TEST)
13.82
QUICK RATIO (ACID-TEST) AVG TTM
9.83
QUICK RATIO (ACID-TEST) AVG 3Y
10.03
QUICK RATIO (ACID-TEST) AVG 5Y
9.81
QUICK RATIO (ACID-TEST) AVG 10Y
8.05
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.66%
CURRENT VS 3Y AVG
+37.86%
CURRENT VS 5Y AVG
+40.90%
CURRENT VS 10Y AVG
+71.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 846 covered companies
CURRENT VS SECTOR MEDIAN
+312.62%
vs the sector median at left
Solid Biosciences Inc.
Market Cap
$681.76M
Quick Ratio (Acid-Test)
13.82
TTM Avg
9.83
3Y Avg
10.03
5Y Avg
9.81
Market Cap
$672.77M
Quick Ratio (Acid-Test)
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
Market Cap
$668.50M
Quick Ratio (Acid-Test)
10.97
TTM Avg
8.63
3Y Avg
10.75
5Y Avg
10.66
Market Cap
$669.77M
Quick Ratio (Acid-Test)
4.79
TTM Avg
3.80
3Y Avg
3.38
5Y Avg
3.21
Market Cap
$666.78M
Quick Ratio (Acid-Test)
8.03
TTM Avg
12.16
3Y Avg
13.50
5Y Avg
14.42
Market Cap
$702.28M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$666.02M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$697.47M
Quick Ratio (Acid-Test)
8.86
TTM Avg
10.22
3Y Avg
11.35
5Y Avg
25.38
Market Cap
$698.13M
Quick Ratio (Acid-Test)
14.20
TTM Avg
2.59
3Y Avg
2.42
5Y Avg
2.06
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | $681.76M | 13.82 | 9.83 | 10.03 | 9.81 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $672.77M | 14.16 | 12.98 | 15.39 | 17.04 |
| Helus Pharma Inc. (HELP)vs › | $668.50M | 10.97 | 8.63 | 10.75 | 10.66 |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | 4.79 | 3.80 | 3.38 | 3.21 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.78M | 8.03 | 12.16 | 13.50 | 14.42 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $702.28M | 19.31 | 14.05 | 7.67 | 5.91 |
| Annexon, Inc. (ANNX)vs › | $666.02M | 5.53 | 8.02 | 10.47 | 14.43 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.47M | 8.86 | 10.22 | 11.35 | 25.38 |
| Anteris Technologies Global Corp. (AVR)vs › | $698.13M | 14.20 | 2.59 | 2.42 | 2.06 |
| Starling Oncology, Inc. (STLN)vs › | $657.39M | 1.15 | 1.35 | 1.35 | 1.35 |
Quick Ratio
13.82
Excludes inventory
Current Ratio
13.82
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 13.82 |
| 2026-03-31 | 13.10 |
| 2025-12-31 | 6.14 |
| 2025-09-30 | 6.74 |
| 2025-06-30 | 9.34 |
| 2025-03-31 | 10.89 |
| 2024-12-31 | 5.20 |
| 2024-09-30 | 7.85 |
| 2024-06-30 | 13.45 |
| 2024-03-31 | 14.94 |
| 2023-12-31 | 8.94 |
| 2023-09-30 | 9.38 |
| 2023-06-30 | 10.56 |
| 2023-03-31 | 9.39 |
| 2022-12-31 | 9.76 |
| 2022-09-30 | 8.72 |
| 2022-06-30 | 7.85 |
| 2022-03-31 | 9.13 |
| 2021-12-31 | 9.43 |
| 2021-09-30 | 10.59 |
| 2021-06-30 | 11.31 |
| 2021-03-31 | 12.02 |
| 2020-12-31 | 6.49 |
| 2020-09-30 | 1.84 |
| 2020-06-30 | 3.31 |
| 2020-03-31 | 4.50 |
| 2019-12-31 | 4.72 |
| 2019-09-30 | 6.78 |
| 2019-06-30 | 5.73 |
| 2019-03-31 | 6.99 |
| 2018-12-31 | 10.31 |
| 2018-09-30 | 13.95 |
| 2018-06-30 | 18.95 |
| 2018-03-31 | 18.57 |
| 2017-12-31 | 6.27 |
| 2017-09-30 | 2.60 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 5.82 |
| 2016-03-31 | 0.00 |
